Key Points
- Moderna has a dominant grasp on the Covid vaccine market — and a significant revenue contributor for years to come.
- Moderna’s second commercialized product is expected to be the RSV vaccine MRNA-1345, a catalyst Moderna shareholders have long awaited.
- Oppenheimer analyst Hartaj Singh kicked off the new year by upgrading MRNA to a Buy.
- 5 stocks we like better than Moderna
Upgrade Now
This premium article is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.
Already have an account? Log in here.
Before you consider Moderna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.
While Moderna currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
